Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May-Jun;16(3):221-228.
doi: 10.21873/cgp.20127.

Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing

Biqiang Zheng  1   2 , Yueting Qu  3 , Jian Wang  3 , Yingqiang Shi  1   2 , Wangjun Yan  4   2
Affiliations

Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing

Biqiang Zheng et al. Cancer Genomics Proteomics. 2019 May-Jun.

Abstract

Background/aim: Undifferentiated pleomorphic sarcomas (UPSs) are difficult to treat, with a high recurrence rate. However, the genetic and molecular characterization of recurrent UPS has not been identified.

Patients and methods: In this study, we investigated the pathogenic and targetable genetic alterations in 16 paired locally pre-recurrent and post-recurrent UPS cases by targeted next-generation sequencing (466 genes).

Results: Sequence variations were most frequently found in TP53 (66%), ATRX (34%), and RB1 (28%). In addition, for the first time, recurrent IL7R gene amplification (19%) and KMT2C gene mutation (16%) were detected in UPS. Interestingly, genetic alterations varied with tumor relapse. Importantly, targetable driver variants were found in recurrent UPS. Mutated genes were correlated with the cell cycle, PI3K/mTOR and RAS/MAPK signaling pathways. TMB was also found to be increased after tumor recurrence (4.6 vs. 7.5 mutations/MB, p=0.0343).

Conclusion: Routine use of targeted next-generation sequencing for recurrent UPS can facilitate timely therapeutic decision-making.

Keywords: NGS; Soft tissue sarcoma; next generation sequencing; recurrence; targetable genetic alterations; undifferentiated pleomorphic sarcoma.

PubMed Disclaimer

Conflict of interest statement

The Authors disclose no potential conflicts of interest regarding this study.

Figures

Figure 1
Figure 1. Landscape of genomic alterations in 16 patients with pre-recurrent UPS identified by targeted next-generation sequencing. Genomic alterations are annotated according to the color panel on the right of the image. Gene amplification (red), Substitution/Indel (green), Truncation (purple), Gene Homozygous Deletion (blue), Fusion/Rearrangement (orange). Alteration rates of genes are displayed on the left of the genomic alterations. Patient ID is shown on the bottom. A: Pre-recurrent UPS.
Figure 2
Figure 2. Landscape of genomic alterations in 16 patients with post-recurrent UPS identified by targeted next-generation sequencing. Genomic alterations are annotated according to the color panel on the right of the image. Gene amplification (red), Substitution/Indel (green), Truncation (purple), Gene Homozygous Deletion (blue), Fusion/Rearrangement (orange). Alteration rates of genes are displayed on the left of the genomic alterations. Patient ID is shown on the bottom. B: Post-recurrent UPS.
Figure 3
Figure 3. Landscape of genomic alterations in 16 paired pre-recurrent UPS and post-recurrent UPS identified by targeted next-generation sequencing. Gene alterations of 32 samples (16 paired) with no less than 2 in frequency were displayed. Genomic alterations were annotated according to the color panel on the right of the image: Gene amplification (red), Substitution/Indel (green), Truncation (purple), Gene Homozygous Deletion (blue), Fusion/Rearrangement (orange). Alteration rates of genes were displayed on the left of the genomic alterations. Patient ID is shown on the bottom. A: pre-recurrent UPS, B: post-recurrent UPS.
Figure 4
Figure 4. TMB is increased after tumor recurrence. (A) Comparison between the pre-recurrent UPS and post-recurrent UPS for TMB (mutations/MB). (B) Comparison of TMB between the pre-recurrent UPS and post-recurrent UPS according to patients who received treatment (chemotherapy and/or radiotherapy) or not in our hospital.
See this image and copyright information in PMC

References

    1. Canter RJ, Beal S, Borys D, Martinez SR, Bold RJ, Robbins AS. Interaction of histologic subtype and histologic grade in predicting survival for soft-tissue sarcomas. J Am Coll Surg. 2010;210(2):191–198 e192. PMID: 20113939. DOI: 10.1016/j.jamcollsurg.2009.10.007. - PubMed
    1. Kelleher FC, Viterbo A. Histologic and genetic advances in refining the diagnosis of "undifferentiated pleomorphic sarcoma". Cancers (Basel) 2013;5(1):218–233. PMID: 24216705. DOI: 10.3390/cancers5010218. - PMC - PubMed
    1. Gibault L, Perot G, Chibon F, Bonnin S, Lagarde P, Terrier P, Coindre JM, Aurias A. New insights in sarcoma oncogenesis: A comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J Pathol. 2011;223(1):64–71. PMID: 21125665. DOI: 10.1002/path.2787. - PubMed
    1. Cancer Genome Atlas Research Network Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171(4):950–965 e928. PMID: 29100075. DOI: 10.1016/j.cell.2017.10.014. - PMC - PubMed
    1. Serrano C, Romagosa C, Hernandez-Losa J, Simonetti S, Valverde C, Moline T, Somoza R, Perez M, Velez R, Verges R, Dominguez R, Carles J, Ramon YCS. Ras/mapk pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas. Cancer. 2016;122(1):99–107. PMID: 26479291. DOI: 10.1002/cncr.29733. - PubMed

Substances